TriSalus Life Sciences, Inc. Cost of Revenue
TriSalus Life Sciences, Inc. (TLSI) reported Cost of Revenue of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- TriSalus Life Sciences, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $1.51M, a 16.32% decline year-over-year.
- TriSalus Life Sciences, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $1.23M, a 17.73% decline year-over-year.
- TriSalus Life Sciences, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $1.76M, a 44.90% increase year-over-year.
- TriSalus Life Sciences, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $1.91M, a 89.84% increase year-over-year.
- TriSalus Life Sciences, Inc. cost of goods and services sold for fiscal 2025 was $6.96M, a 69.75% increase from fiscal 2024.
- TriSalus Life Sciences, Inc. cost of goods and services sold for fiscal 2024 was $4.10M, a 57.50% increase from fiscal 2023.
- TriSalus Life Sciences, Inc. cost of goods and services sold for fiscal 2023 was $2.60M, a 15.37% increase from fiscal 2022.
- TriSalus Life Sciences, Inc. cost of goods and services sold for fiscal 2022 was $2.26M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-06 | $2.74M 10-Q · filed 2026-08-06 | $4.50M derived: sum of 3 quarters · filed 2026-08-06 | $6.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.23M 10-Q · filed 2026-05-12 | $2.99M derived: sum of 2 quarters · filed 2026-05-12 | $4.90M derived: sum of 3 quarters · filed 2026-05-12 | $6.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.67M derived: sum of 2 quarters · filed 2026-03-05 | $5.47M derived: sum of 3 quarters · filed 2026-08-06 | $6.96M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.91M 10-Q · filed 2025-11-13 | $3.71M derived: sum of 2 quarters · filed 2026-08-06 | $5.20M 10-Q · filed 2025-11-13 | $6.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-06 | $3.30M 10-Q · filed 2026-08-06 | $4.51M derived: sum of 3 quarters · filed 2026-08-06 | $5.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-12 | $2.71M derived: sum of 2 quarters · filed 2026-05-12 | $3.71M derived: sum of 3 quarters · filed 2026-05-12 | $4.63M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.22M derived: sum of 2 quarters · filed 2026-03-05 | $3.13M derived: sum of 3 quarters · filed 2026-03-05 | $4.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-13 | $1.92M derived: sum of 2 quarters · filed 2025-11-13 | $2.89M 10-Q · filed 2025-11-13 | $3.47M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $912.00K 10-Q · filed 2025-08-12 | $1.88M 10-Q · filed 2025-08-12 | $2.46M derived: sum of 3 quarters · filed 2025-08-12 | $3.05M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $971.00K 10-Q · filed 2025-05-15 | $1.55M derived: sum of 2 quarters · filed 2025-05-30 | $2.14M derived: sum of 3 quarters · filed 2025-05-30 | $2.91M derived: sum of 4 quarters · filed 2025-05-30 |
| 2023-12-31 | $582.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-05-30 | $1.17M derived: sum of 2 quarters · filed 2025-05-30 | $1.94M derived: sum of 3 quarters · filed 2025-05-30 | $2.60M 10-K/A · filed 2025-05-30 |
| 2023-09-30 | $589.00K 10-Q · filed 2024-11-14 | $1.36M derived: sum of 2 quarters · filed 2024-11-14 | $2.02M 10-Q · filed 2024-11-14 | $2.84M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $772.00K 10-Q · filed 2024-08-14 | $1.43M 10-Q · filed 2024-08-14 | $2.25M derived: sum of 3 quarters · filed 2024-08-14 | $2.95M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $662.00K 10-Q · filed 2024-05-15 | $1.48M derived: sum of 2 quarters · filed 2024-05-15 | $2.18M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $816.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $1.52M derived: sum of 2 quarters · filed 2024-04-11 | $2.26M 10-K · filed 2024-04-11 | |
| 2022-09-30 | $701.00K 10-Q · filed 2023-11-14 | $1.44M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |